| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192591 | Journal of Thoracic Oncology | 2016 | 6 Pages |
Abstract
In a proteomics-enriched cohort of patients with NSCLC and PS2, pharmacodynamically separated erlotinib plus chemotherapy had better efficacy than did erlotinib alone and surpassed the protocol-specified benchmark of PFS of at least 3 months required for further study.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Primo N. MD, James MS, Paul J. MD, Mary W. PhD, Stephen K. MD, Wallace L. MD, Fred R. MD, PhD, Philip C. PhD, David R. MD,